Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04763356 · ClinicalTrials.gov registry record · NA

Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy

A NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by University of Vermont.

Recruiting
Registry status
NA
Development phase
422
Enrollment target
3
Study locations

NCT04763356: Recruiting NA study of Chemotherapy-induced Peripheral Neuropathy, sponsored by University of Vermont.

NCT04763356 is a NA study of Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 422 participants, above the 124-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (240% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04763356, a NA study of Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by University of Vermont.

RECRUITING
Registry status
NA
Development phase
422 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any treatment they feel is appropriate. In the second group, if the symptoms meet the criteria for eligibility they will receive a phone call from a nurse practitioner either the same day or next day, depending on the time symptoms were logged. That nurse practitioner will determine the correct CIPN treatment using an algorithm and prescribe it. The study will track the severity of symptoms over time as well as looking at the impact on treatments for CIPN (medications and referrals).

Primary Outcome

The Neuropathy Total Symptoms Score is a the NTSS- 6, a well validated patient reported neuropathy specific outcome measure. Scores range from 0 to 21.96. Higher scores denote worse outcomes

Interventions

  • OTHER Symptom Care at Home with NP follow up

Study Locations (3)

Utah

  • University of Utah - Salt Lake City

Vermont

  • University of Vermont - Burlington

Virginia

  • Virginia Commonwealth University Massey Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 422 participants
Start Date 2023-01-10
Est. Completion 2026-09-30
Phase NA
University of Vermont

162 total trials

What NCT04763356 shows while recruiting

NCT04763356 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (240% higher).

The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Symptom Care at Home with NP follow up is the first listed.

NCT04763356 reports a single indexed study location in Utah, Vermont, Virginia.

Frequently Asked Questions

What is clinical trial NCT04763356 about?

NCT04763356 is a clinical study titled "Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy". This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for ...

What is the current status of trial NCT04763356?

This trial is currently recruiting. It is a NA study. The enrollment target is 422 participants. The study started on 2023-01-10. Estimated completion is 2026-09-30.

What conditions does trial NCT04763356 study?

This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.

What interventions are being tested in trial NCT04763356?

The interventions under investigation include: Symptom Care at Home with NP follow up (OTHER).

Who is sponsoring clinical trial NCT04763356?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04763356 being conducted?

This trial has 3 study locations across Utah, Vermont, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chemotherapy-induced Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04763356's enrollment target sits among peer trials

422 2nd of 29 the highest of 29 other Chemotherapy-induced Peripheral Neuropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06837246 · 422 participants · NA

    A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

  • NCT07298967 · 422 participants · NA

    ORCHARDS-AIR Study

  • NCT06935591 · 423 participants · NA

    Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

  • NCT07128628 · 423 participants · Phase 2

    A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04763356, the US trial registry maintained by the National Library of Medicine. NCT04763356 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.